Brean Murray Carret & Co Increases Price Target on ARIAD (ARIA) to $35
Tweet
Share
E-mailGet Alerts ARIA Hot Sheet
Price: $26.03 --0%
Rating Summary:
10 Buy, 12 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 6 | New: 3
Rating Summary:
10 Buy, 12 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 6 | New: 3
Join SI Premium – FREE
Brean Murray Carret & Co. reiterated a Buy rating on ARIAD Pharmaceuticals (NASDAQ: ARIA) and increased their price target to $35.00 (from $19.00).
“Ariad presented positive interim Phase 1 data at the Congress of the European Society for Medical Oncology from the ongoing Phase 1 portion of its Phase 1/2 trial of AP26113 in patients with advanced solid tumors, most of whom (29/34) were non-small cell lung cancer (NSCLC) patients,” said analyst Jonathan Aschoff.
He considers the AP26113 data to be highly encouraging and noted a parallel between AP26113 and ponatinib, which increases his optimism of a second Ariad drug taking an abbreviated path to market.
For an analyst ratings summary and ratings history on ARIAD Pharmaceuticals click here. For more ratings news on ARIAD Pharmaceuticals click here.
Shares of ARIAD Pharmaceuticals closed at $24.21 yesterday.
“Ariad presented positive interim Phase 1 data at the Congress of the European Society for Medical Oncology from the ongoing Phase 1 portion of its Phase 1/2 trial of AP26113 in patients with advanced solid tumors, most of whom (29/34) were non-small cell lung cancer (NSCLC) patients,” said analyst Jonathan Aschoff.
He considers the AP26113 data to be highly encouraging and noted a parallel between AP26113 and ponatinib, which increases his optimism of a second Ariad drug taking an abbreviated path to market.
For an analyst ratings summary and ratings history on ARIAD Pharmaceuticals click here. For more ratings news on ARIAD Pharmaceuticals click here.
Shares of ARIAD Pharmaceuticals closed at $24.21 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi raises EquipmentShare price target to $22, keeps Neutral
- JPMorgan Resumes SanDisk (SNDK) at Overweight
- Kepler Cheuvreux Upgrades Swissquote Group Holding SA (SQN:SW) to Buy
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Analyst PT ChangeRelated Entities
Brean Murray Carret & Co., Raising PricesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
